GLP

News • Pharma

Lilly to Build $6.5 Billion US Pharmaceutical Plant

Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Houston, Texas.

News

Novo Nordisk Invests $1.09 Billion in Brazil

Novo Nordisk continues its sizeable manufacturing investments to meet increasing drug demands.

News

Reaction Biology Buys Germany’s Bioassay

US contract research organization Reaction Biology has acquired German contract laboratory Bioassay Labor für biologische Analytik and its wholly owned subsidiary Peptide Specialty Laboratories (PSL).

Top-Feature

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

Expert Insights

Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

Novo Nordisk A/S

Eli Lilly and Company

GLP